PT-141: reconstituting part of a vial

A post on r/Peptides asks a question that comes up often among people handling research-grade PT-141 (bremelanotide) for the first time: the lyophilised cake inside the vial looks like a solid disc or puck, not a loose powder. Can it be physically split into two portions, leaving half dry in the vial for later? The short answer is: the FDA-approved product does not come in this form at all, and for the research-grade vials the community uses, splitting the dry cake is not how peptide manufacturers intend the product to be handled. Here is what the primary sources actually say.

Vyleesi is a pre-filled autoinjector, not a lyophilised vial

The FDA-approved bremelanotide product, Vyleesi, is supplied as a 1.75 mg/0.3 mL clear solution in a single-dose, disposable pre-filled autoinjector^[1]. There is no lyophilised powder to reconstitute, no solvent to add, and no partially-used portion to store: each autoinjector is for one injection and must be discarded after use. The prescribing information specifies storage at or below 25 degrees C, no freezing, and protection from light^[1]. This is the only product for which the originator, Cosette Pharmaceuticals, has published stability data in the public domain.

The research-grade PT-141 sold by peptide suppliers is a different presentation entirely. It typically arrives as a lyophilised (freeze-dried) cake in a sealed multi-dose vial, and the buyer adds bacteriostatic water to reconstitute it. The originator has published no stability data for that format, because it is not an FDA-approved presentation.

What lyophilisation does and why splitting the cake matters

Lyophilisation removes water from a peptide solution by freezing it and then sublimating the ice under vacuum. The result is a dry, porous solid that is far more stable than a solution at room temperature. Reconstituting it means adding a precise volume of solvent to dissolve the cake and arrive at a known concentration. The process is designed around the assumption that the entire cake goes into solution at once: the cake's mass, the excipients distributed through it, and the volume of solvent added together determine the final concentration^[2].

If you split the cake before reconstitution, you are splitting it into portions of unknown weight. Lyophilised peptide cakes are not homogeneous slabs: the drying process can concentrate material unevenly, and excipients may not distribute evenly through the disc. A visual half of the cake is not necessarily half the active ingredient. The result is a reconstituted solution at an unknown concentration, not half the nominal dose per millilitre.

Reconstituted peptide stability and the 28-day window

The original question is partly about whether the dry cake can be kept partially intact while the reconstituted portion is used up. This assumes that reconstituted bremelanotide has a short shelf life compared with the dry form, which is correct in principle. Once a peptide is in solution, hydrolysis and other degradation reactions begin. The CDC's injection-safety guidance, referencing USP General Chapter 797, states that a multi-dose vial that has been needle-punctured should be dated and discarded within 28 days, unless the manufacturer specifies otherwise^[3]. For research-grade PT-141, no manufacturer has published a peer-reviewed post-reconstitution stability study, so the 28-day rule is the conservative clinical standard to apply.

Refrigeration at 2 to 8 degrees C (36 to 46 degrees F) and protection from light extend the window within which a reconstituted solution remains usable, but they do not stop degradation: they slow it^[2]. The lyophilised form, kept sealed, can remain stable for much longer, which is why the original question has intuitive appeal. Keeping half the dose dry and reconstituting it later would preserve it better, if you could split it accurately, which you cannot without weighing equipment.

What the literature actually says about the planned approach

The FDA-approved Vyleesi label makes clear this question does not arise for the approved product: single-dose autoinjectors leave no reconstitution decision for the user^[1]. For the research-grade format, the practical options that preserve dose accuracy are: reconstitute the entire vial, calculate the volume per desired dose, draw and inject that volume, and refrigerate the remainder in the sealed vial for use within the beyond-use window. That approach keeps the concentration known and the remainder in solution, where the 28-day clock is running but at least the concentration is not uncertain.

The alternative, using more solvent than the standard volume to produce a lower-concentration solution that lasts fewer doses before the beyond-use date arrives, is a calculation error waiting to happen. Adding twice the recommended solvent volume does not necessarily halve the degradation rate.

What we do not yet know

The gap in the public literature is that no independent, peer-reviewed stability study exists for reconstituted research-grade bremelanotide stored at refrigerator temperature. The Vyleesi prescribing information does not address lyophilised vials because none exist in the approved product. Community members sharing real-world degradation observations, stored samples, and HPLC assay results would contribute useful signal, but that data is anecdotal rather than controlled. The 28-day figure from CDC and USP 797 is a conservative clinical standard, not a bremelanotide-specific expiration. Whether reconstituted PT-141 degrades meaningfully in 10 days at 4 degrees C, or remains stable for 28, is not established in the literature we were able to verify.

This article is for educational purposes only. It describes what the FDA label and published pharmacological literature state. It does not advise on sourcing, reconstituting, or using bremelanotide in any context. Decisions about any injectable substance belong with a licensed prescriber. See our PT-141 regulation pages for jurisdiction-specific legal status.